Expert Interview
Digging into the Phase 1 data on Affimed's AFM24 and atezolizumab combination in patients with EGFR+ solid tumors
Ticker(s): AFMDInstitution: Advanced Care Oncology And Hematology Associates
- Medical Oncologist & Partner at ACOHA (private practice in New Jersey); fellowship trained at New York Presbyterian-Columbia University Medical Center.
- Manages ~400 patients with solid tumors and 25 patients with gastroesophageal junction cancer.
- Lectures widely on Gastrointestinal and Genitourinary malignancies.
What percent of your patients could benefit from upcoming novel drugs? How much need is there for a tetravalent, bispecific innate cell engager such as AFM24?
Added By: max_adminCould you the mechanism of action behind the drug’s ability to bind to CD16A on innate immune cells and EGFR, and how that translates into better patient outcomes? Where do you see the benefits of this approach vs standard care?
Added By: max_adminHow likely is it for AFM24 + Atezolizumab 1PR (Gastric) or 1SD (Pancreatic) to become the preferred method of treatment, based on the recent data?
Added By: max_adminThe company has stated in the past that every patient overexpressing EGFR could be eligible for treatment with AFMD24 irrespective of mutational status. How would you assess that statement?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
